Peer-Reviewed Publication
Breast2026;90104912.September 11, 2026Journal Article

Transcriptomic signatures of mind-body transformations therapy in breast cancer: Downregulation of the interferon signaling pathway.

Stefania Cocco1, Mauro Cozzolino2, Michela Piezzo3, Giovanna Celia4, Daniela Barberio5, Valentina Abate5, Alessandra Calabrese3, Claudia Von Arx3, Rossana Di Rienzo3, Susan Costantini6, Alfredo Budillon7, Michelino De Laurentiis8
1Department of Breast and Thoracic Oncology, Division of Breast Medical Oncology, Istituto Nazionale Tumori IRCCS Fondazione G. Pascale, Napoli, Italy. Electronic address: s.cocco@istitutotumori.na.it.
2Department of Human, Philosophical and Educational Sciences, University of Salerno, Salerno, Italy.
3Department of Breast and Thoracic Oncology, Division of Breast Medical Oncology, Istituto Nazionale Tumori IRCCS Fondazione G. Pascale, Napoli, Italy.
4Department of Theoretical and Applied Sciences, Ecampus University, Novedrate, Italy.
5Departmental Simple Unit of Psycho-oncology, Istituto Nazionale Tumori IRCCS Fondazione G. Pascale, Napoli, Italy.
6Experimental Pharmacology Unit, Istituto Nazionale Tumori IRCCS Fondazione G. Pascale, Napoli, Italy.
7Scientific Directorate, Istituto Nazionale Tumori IRCCS Fondazione G. Pascale, Napoli, Italy.
8Department of Breast and Thoracic Oncology, Division of Breast Medical Oncology, Istituto Nazionale Tumori IRCCS Fondazione G. Pascale, Napoli, Italy. Electronic address: m.delaurentiis@istitutotumori.na.it.

Abstract

BACKGROUND: Growing evidence has shown that Mind-Body Transformations-Therapies (MBT-T) are able to modulate chronic inflammation, a well-known driver of cancer progression and drug resistance. In our previous work, we showed that a specific MBT-T protocol was able to reduce the release of various pro-inflammatory cytokines and chemokines in the sera of patients with breast cancer that completed a…

Create a free account to keep reading

Free members get 10 full research views every month across publications, clinical trials, FDA clearances, adverse events, and NIH grants. No credit card required.

Want unlimited research access? See Pro plans

Data Accuracy Notice: Research intelligence on Health AI Central is aggregated from public sources (PubMed, ClinicalTrials.gov, FDA, NIH, CMS, and others) and refreshed nightly. Classifications and derived metrics are produced by automated methods described in our Methodology. We recommend verifying critical data points against the primary sources before making decisions.